• SPX
  • $5,973.10
  • 0.74 %
  • $44.06
  • DJI
  • $43,729.34
  • -0 %
  • -$0.59
  • N225
  • $39,472.19
  • 0.23 %
  • $91.00
  • FTSE
  • $8,140.74
  • -0.32 %
  • -$25.94
  • IXIC
  • $19,269.46
  • 1.51 %
  • $285.99
Takeda Pharmaceutical Company Limited (TAK) Stock Price, News & Analysis

Takeda Pharmaceutical Company Limited (TAK) Stock Price, News & Analysis

Currency in USD Disclaimer

$13.86

$0.07

(0.51%)

Day's range
$13.82
Day's range
$13.9
50-day range
$13.5
Day's range
$15
  • Country: JP
  • ISIN: US8740602052
52 wk range
$12.58
Day's range
$15.08


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 0.55
  • Piotroski Score 6.00
  • Grade Outperform
  • Symbol (TAK)
  • Company Takeda Pharmaceutical Company Limited
  • Price $13.86
  • Changes Percentage (0.51%)
  • Change $0.07
  • Day Low $13.82
  • Day High $13.90
  • Year High $15.08

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

  • Last Earnings N/A
  • Ex-Dividend for 5/16 Dividend 09/30/2024
  • Dividend Payable N/A
  • Today N/A
  • Next Earnings (Estimated) 01/29/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Buy
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $0.29
  • Trailing P/E Ratio 46.45
  • Forward P/E Ratio 46.45
  • P/E Growth 46.45
  • Net Income $144.07 B

Income Statement

Quarterly

Annual

Latest News of TAK

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.